Join Here   |   Log In

Progesterone: creation, receptors, effects, and metabolism

Key takeaways:
~ Progesterone is an important hormone in women’s health, regulating menstruation, and for pregnancy.
~ Progesterone is important for everyone, men and women, for brain health and overall well-being.
~ Genetic variants play a role in how your body makes progesterone, how it uses progesterone, and how it breaks down and eliminates progesterone.

Members will see their genotype report below and the solutions in the Lifehacks section. Consider joining today

What does progesterone do in the body?

Progesterone is a hormone made by both men and women. It plays a greater role in premenopausal women, and while that will be the main focus here, the same mechanisms take place for men to a lesser degree.

As a hormone, progesterone can interact with different receptors in the nucleus of cells and turn on or off the production of other genes. Progesterone can also act directly on non-nuclear receptors in the ovaries.[ref]

In the brain, progesterone acts on the HPA axis (hypothalamus, pituitary, adrenals) and regulates the production of luteinizing hormone (LH) in women. This is a feedback loop between the ovarian production of progesterone and the control of LH from the hypothalamus.

Progesterone also affects mood and the way people feel and behave. In general, progesterone reduces sexual desire in women as well as decreases aggression and anxiety. When it comes to PMS (irritability, anxiety, and aggression), there is a lower-than-normal level of progesterone.

In the brain, progesterone metabolizes into allopregnanolone, which is neuroprotective in brain trauma.[ref]

How is progesterone made?

Progesterone’s generation in the body occurs during a multistep process that starts with LDL cholesterol.

The LDL cholesterol is taken into cells via cholesterol receptors, where it is transferred into the mitochondria to be converted into pregnenolone.

Pregnenolone is released by the mitochondria and can take two paths, depending on the organ where it is created:[ref]

  • In the adrenals, pregnenolone turns into DHEA, androstenediol, and 17-alpha hydroxypregnenolone. From here, it generally gets converted into glucocorticoids and androgens.
  • In the female reproductive organs, pregnenolone becomes progesterone and 17-alpha hydroxypregnenolone. From here, it can become androstenedione and then estrogens. Progesterone from the reproductive system can circulate in the bloodstream, where it can then act on the regions of the brain that are controlling the reproductive hormones.

Diagram of steroid hormone production[ref]:

Mechanism of action for progesterone:

Let’s get into the details of how progesterone works to turn on and off genes.

Progesterone is a lipophilic hormone, so it can diffuse across cell membranes. Within the nucleus of the cell, it attaches to progesterone receptors. These progesterone receptors come in a couple of different sizes and are denoted as PR-A and PR-B. The different flavors of receptors are active in different tissues. PR-A is important for ovulation in the ovaries, and PR-B is part of the development of mammary glands.[ref]

Progesterone Receptor Types

Receptor Location/Function
PR-A Ovary (ovulation)
PR-B Mammary glands (development)
Membrane-associated Cholesterol/steroid metabolism, iron balance

Once progesterone binds to the receptor, it will bind to certain spots on the DNA to recruit other proteins to the site. These regulatory proteins then activate or repress the transcription of certain genes.

It gets a little complex – but just think of it as progesterone causing other genes to get turned on (via the progesterone receptor). These other genes help prepare the uterus for pregnancy, like growth factors needed for regenerating the uterine lining.[ref]

Interestingly, other genes regulated by progesterone include a couple of important circadian rhythm genes.

Additionally, progesterone can act on specific membrane-associated progesterone receptors. These receptors affect cholesterol and steroid biosynthesis, metabolism, as well as balancing iron.[ref]

Balancing act: Estrogen vs. Progesterone

Progesterone plays a role in preparing the uterus for implantation of the fertilized egg, and then, if pregnancy occurs, progesterone levels rise over the course of the pregnancy and are essential for maintaining the pregnancy.[ref]

In a sense, progesterone is balancing out some of the growth that estrogen is promoting. Estrogen stimulates the endometrium, and progesterone is coming along to regulate the gene expression of the fibroblast growth factors.[ref]

Table: Progesterone vs. Estrogen

Estrogen Progesterone
Stimulates endometrial growth Regulates endometrial growth, prepares uterus for implantation
Promotes fibroblast growth factors Regulates gene expression of growth factors
Increases progesterone receptor expression Inhibits estrogen receptor expression

When not pregnant, menstruation occurs when progesterone levels drop at the end of the menstrual cycle. The black line in the image below shows how progesterone rises after ovulation (by 10 to 35-fold) and drops at the start of menstruation.[ref]

In the uterus, progesterone receptor expression is dependent on and responsive to the amount of estrogen. Additionally, estrogen receptor expression is inhibited by progesterone, forming a feedback loop.[ref]

Metabolism of progesterone:

Like all hormones created in the body, progesterone needs to be broken down (metabolized) and eventually excreted or recycled.

The metabolites of progesterone can also play an active role in the body. For example, allopregnanolone is important in brain health.

The steroid enzyme 5α-reductase (5αR) acts on progesterone, converting it to 5α-dihydroprogesterone (DHP). 5αR also metabolizes testosterone and deoxycorticosterone.

DHP, the progesterone metabolite, is active in the brain as a neuroactive steroid that modulates the GABA-A receptors. (Read all about GABA here) Both progesterone and the DHP metabolite are important in the brain. Animal studies show that changing 5αR levels (via drugs such as finasteride) affects behavior and brain function.[ref]

Additionally, progesterone and synthetic progestin are metabolized through the CYP450 enzymes, a family of enzymes responsible for breaking down many substances made by the body as well as toxins and medications. CYP3A4 is the main route of metabolism[ref], and CYP2C19 also plays a role.

 

Recap: How is progesterone broken down?
~ Metabolized by 5α-reductase and CYP450 enzymes (mainly CYP3A4, CYP2C19)
~ Produces neuroactive metabolites like DHP and allopregnanolone

Progesterone pills and supplements:

Progesterone can be a part of birth control pills (estrogen + progesterone), or it can be given alone (e.g., Depo-Provera birth control shots).

There are four main ways of getting additional progesterone (synthetic progestins or bioidentical) into the body:[ref]

  • Transdermal progesterone cream is generally not enough to raise the plasma concentration of progesterone significantly – at least not compared with other methods.
  • The absorption of oral progesterone pills occurs in the intestines. It then travels to the liver and where it mostly breaks down. Thus, oral doses of progesterone must be really high to get any of it past the liver.
  • Vaginal progesterone suppositories make it into the uterus and endometrium more readily.
  • Progesterone shots work to increase progesterone levels, but there is poor compliance.

Normally, progesterone rises to high levels during pregnancy, which is essential for maintaining pregnancy. Sometimes women with a high risk of miscarriage are given progesterone.

Blocking the progesterone receptor is a way to terminate a pregnancy during the first two months. Mifepristone, or RU-486, is the name of this drug.

Ella (ulipristal acetate) is another medication that acts on the progesterone receptor.[ref] Known as the morning-after pill, Ella is sold as a prescription emergency contraceptive in the US.

Synthetic progesterone medications known as progestins or progestogens are often used as birth control or for menopausal hormone therapy.

Etonogestrel, a synthetic progestin, can be implanted into the arm for 1-3 years of birth control. Some people carry an extra copy of the CYP3A7 gene. This gene codes for an enzyme needed for a baby’s development but usually switches off at birth. About 4% of the population carries an additional copy of the CYP3A7 gene (not covered by AncestryDNA or 23andMe data), which affects the metabolism of progestins (progestogens) as well as other steroid hormones. It can also affect the efficacy of etonogestrel as a birth control method.[ref]

Table: Progesterone Supplementation Methods

Method Notes/Effectiveness
Transdermal cream Generally insufficient to significantly raise blood levels
Oral pills High first-pass metabolism in liver, requires high doses
Vaginal suppositories Direct effect on uterus/endometrium
Injections (shots) Effective, but compliance may be poor

Progesterone Genotype Report:

Members: Log in to see your data below.
Not a member? Join here.


Access this content:

An active subscription is required to access this content.

Join as a member



Lifehacks:

Please be sure to talk with your doctor if you have questions on whether supplemental progesterone is right for you. Your doctor can also help you with testing your progesterone and estrogen levels. Below are some studies that shed light on the topic.

Studies on supplemental progesterone:

Bioidentical progesterone creams:

Access this content:

An active subscription is required to access this content.

Join as a member



Related Articles and Topics:

Estrogen: How It Is Made and How We Get Rid of It

PMS, Genetics, and Solutions


References:

Chen, Zhen, et al. “Contribution of PGR Genetic Polymorphisms to the Pathogenesis of Endometrial Cancer: A Meta-Analysis.” Journal of Cancer Research and Therapeutics, vol. 11, no. 4, 2015, pp. 810–17. PubMed, https://doi.org/10.4103/0973-1482.146124.
Collaborative Group on Hormonal Factors in Breast Cancer. “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence.” Lancet (London, England), vol. 394, no. 10204, Sept. 2019, pp. 1159–68. PubMed, https://doi.org/10.1016/S0140-6736(19)31709-X.
Ghali, Rabeb M., et al. “Progesterone Receptor (PGR) Gene Variants Associated with Breast Cancer and Associated Features: A Case-Control Study.” Pathology Oncology Research: POR, vol. 26, no. 1, Jan. 2020, pp. 141–47. PubMed, https://doi.org/10.1007/s12253-017-0379-z.
Godar, Sean C., et al. “The Steroidogenesis Inhibitor Finasteride Reduces the Response to Both Stressful and Rewarding Stimuli.” Biomolecules, vol. 9, no. 11, Nov. 2019, p. 749. PubMed Central, https://doi.org/10.3390/biom9110749.
Jasienska, Grazyna, et al. “Apolipoprotein E (ApoE) Polymorphism Is Related to Differences in Potential Fertility in Women: A Case of Antagonistic Pleiotropy?” Proceedings of the Royal Society B: Biological Sciences, vol. 282, no. 1803, Mar. 2015, p. 20142395. PubMed Central, https://doi.org/10.1098/rspb.2014.2395.
Kim, J. Julie, et al. “Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer.” Endocrine Reviews, vol. 34, no. 1, Feb. 2013, pp. 130–62. PubMed Central, https://doi.org/10.1210/er.2012-1043.
Klein, Kathrin, and Ulrich M. Zanger. “Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the ‘Missing Heritability’ Problem.” Frontiers in Genetics, vol. 4, Feb. 2013, p. 12. PubMed Central, https://doi.org/10.3389/fgene.2013.00012.
———. “Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the ‘Missing Heritability’ Problem.” Frontiers in Genetics, vol. 4, Feb. 2013, p. 12. PubMed Central, https://doi.org/10.3389/fgene.2013.00012.
Lee, Su-Jun, and Joyce A. Goldstein. “Functionally Defective or Altered CYP3A4 and CYP3A5 Single Nucleotide Polymorphisms and Their Detection with Genotyping Tests.” Pharmacogenomics, vol. 6, no. 4, June 2005, pp. 357–71. PubMed, https://doi.org/10.1517/14622416.6.4.357.
Manuck, Tracy A., Heather D. Major, et al. “Progesterone Receptor Genotype, Family History, and Spontaneous Preterm Birth.” Obstetrics and Gynecology, vol. 115, no. 4, Apr. 2010, pp. 765–70. PubMed, https://doi.org/10.1097/AOG.0b013e3181d53b83.
Manuck, Tracy A., Yinglei Lai, et al. “Progesterone Receptor Polymorphisms and Clinical Response to 17-Alpha-Hydroxyprogesterone Caproate.” American Journal of Obstetrics and Gynecology, vol. 205, no. 2, Aug. 2011, p. 135.e1-135.e9. PubMed Central, https://doi.org/10.1016/j.ajog.2011.03.048.
Meenakumari, K. J., et al. “Effects of Metformin Treatment on Luteal Phase Progesterone Concentration in Polycystic Ovary Syndrome.” Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas, vol. 37, no. 11, Nov. 2004, pp. 1637–44. PubMed, https://doi.org/10.1590/s0100-879×2004001100007.
Mikael Häggström, et al. “Diagram of the Pathways of Human Steroidogenesis.” [[WikiJournal of Medicine|WikiJournal of Medicine]], vol. 1, no. 1, Apr. 2014, https://doi.org/10.15347/WJM/2014.005.
Palmirotta, Raffaele, et al. “Progesterone Receptor Gene (PROGINS) Polymorphism Correlates with Late Onset of Migraine.” DNA and Cell Biology, vol. 34, no. 3, Mar. 2015, pp. 208–12. PubMed Central, https://doi.org/10.1089/dna.2014.2534.
Patel, Bansari, et al. “Role of Nuclear Progesterone Receptor Isoforms in Uterine Pathophysiology.” Human Reproduction Update, vol. 21, no. 2, Mar. 2015, pp. 155–73. PubMed Central, https://doi.org/10.1093/humupd/dmu056.
Pearce, C. L., et al. “Progesterone Receptor Variation and Risk of Ovarian Cancer Is Limited to the Invasive Endometrioid Subtype: Results from the Ovarian Cancer Association Consortium Pooled Analysis.” British Journal of Cancer, vol. 98, no. 2, Jan. 2008, pp. 282–88. PubMed, https://doi.org/10.1038/sj.bjc.6604170.
Quinney, Sara K., et al. “Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism.” Fetal and Pediatric Pathology, vol. 36, no. 5, Oct. 2017, pp. 400–11. PubMed Central, https://doi.org/10.1080/15513815.2017.1354411.
Richards-Waugh, Lauren L., et al. “Fatal Methadone Toxicity: Potential Role of CYP3A4 Genetic Polymorphism.” Journal of Analytical Toxicology, vol. 38, no. 8, Oct. 2014, pp. 541–47. PubMed, https://doi.org/10.1093/jat/bku091.
Ryu, Chang S., et al. “Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions – Focus on Interactions with Cytochromes P450.” Frontiers in Pharmacology, vol. 8, Mar. 2017. Frontiers, https://doi.org/10.3389/fphar.2017.00159.
Taraborrelli, Stefania. “Physiology, Production and Action of Progesterone.” Acta Obstetricia et Gynecologica Scandinavica, vol. 94, no. S161, Nov. 2015, pp. 8–16. DOI.org (Crossref), https://doi.org/10.1111/aogs.12771.
Terry, Kathryn L., et al. “Genetic Variation in the Progesterone Receptor Gene and Ovarian Cancer Risk.” American Journal of Epidemiology, vol. 161, no. 5, Mar. 2005, pp. 442–51. PubMed Central, https://doi.org/10.1093/aje/kwi064.
Vang, Alecia, et al. “Progesterone Receptor Gene Polymorphisms and Breast Cancer Risk.” Endocrinology, vol. 164, no. 4, Jan. 2023, p. bqad020. PubMed Central, https://doi.org/10.1210/endocr/bqad020.
Wren, Barry G. “Transdermal Progesterone Creams for Postmenopausal Women: More Hype than Hope?” Medical Journal of Australia, vol. 182, no. 5, Mar. 2005. eMJA, https://www.mja.com.au/journal/2005/182/5/transdermal-progesterone-creams-postmenopausal-women-more-hype-hope.
Zubiaur, Pablo, et al. “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally.” Advances in Therapy, vol. 36, no. 10, Oct. 2019, pp. 2744–55. PubMed, https://doi.org/10.1007/s12325-019-01075-5.
http://www.snpedia.com/index.php/Rs4244285. Accessed 18 Mar. 2026.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.